Recent Publications

Summary

Auxilius Pharma, featured in a recent CXO PharmaShots Talk, is a pharmaceutical company co-founded by Jed Litwiniuk, the CEO, and Uwe Tigör, the CMO. Both founders have a background in medicine and public health, with a focus on cardiovascular disease. The company aims to address gaps in heart disease treatment through "value-added" medications that enhance existing drugs to improve clinical outcomes with manageable development risks. Its flagship product, AUX-001, targets chronic stable angina (CSAP), a widespread condition in the U.S. and Europe. AUX-001’s formulation addresses both the underlying disease and symptoms, aiming to simplify treatment by reducing the number of medications patients take per day.

Auxilius Pharma’s commitment to innovation extends to its research and development pipeline, with additional assets AUX-002 and AUX-003 aimed at creating fixed-dose combinations to improve drug adherence and efficacy. These treatments aim to meet the growing need for effective anti-anginal drugs as patients live longer with chronic cardiovascular conditions. The company's work in optimizing dosage and release profiles highlights a broader mission to provide cardiovascular solutions that balance efficacy, safety, and patient accessibility, offering hope for more effective and streamlined treatment options for heart disease.

About chronic stable angina

Chronic stable angina pectoris is a type of angina that is characterised by recurring chest pain or discomfort. It occurs when there is reduced blood flow to the heart muscle due to narrowed or blocked coronary arteries. The chest pain in chronic stable angina is usually triggered by physical exertion or emotional stress and typically lasts for a few minutes.

GlobalData estimates that sales of the angina market (stable, microvascular, variant) to be approximately $7.8bn across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) in 2028. GlobalData is the parent company of the Clinical Trials Arena.

About Auxilius Pharma

Auxilius Pharma is a privately held pharmaceutical company that commenced operations in 2019. Auxilius operates in the space of value-added medicines and brings innovation to areas of high unmet need for patients with diseases such as chronic stable angina pectoris that aim to impact public health positively. Auxilius Pharma’s R&D Strategy is driven by patients' need for affordable medications to manage their chronic conditions in the US and on other major markets.